{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:52:12Z","timestamp":1780649532329,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174352"],"award-info":[{"award-number":["82174352"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008010","name":"National Engineering College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178053","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T23:59:35Z","timestamp":1755647975000},"page":"178053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Real-world drug safety study of somatostatin analogs based on the food and drug administration adverse event reporting system database"],"prefix":"10.1016","volume":"1005","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8892-1958","authenticated-orcid":false,"given":"Wangyu","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178053_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40268-021-00342-7","article-title":"Incident gallstones during somatostatin analog treatment are associated with acute biliary complications especially after discontinuation","volume":"21","author":"Aapkes","year":"2021","journal-title":"Drugs R&D"},{"key":"10.1016\/j.ejphar.2025.178053_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9610(91)90381-M","article-title":"Why does somatostatin cause gallstones?","volume":"161","author":"Ahrendt","year":"1991","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.ejphar.2025.178053_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther Adv Drug Saf"},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2025.178053_bib4","first-page":"S216","article-title":"Long-acting formulations of somatostatin analogues","volume":"31","author":"Anthony","year":"1999","journal-title":"Ital. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2025.178053_bib5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/BF03346419","article-title":"Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients","volume":"31","author":"Attanasio","year":"2008","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.ejphar.2025.178053_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1365-2265.2003.01876.x","article-title":"Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment","volume":"59","author":"Baldelli","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejphar.2025.178053_bib7","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2165\/00003495-198938050-00002","article-title":"Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion","volume":"38","author":"Battershill","year":"1989","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2025.178053_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0166-2236(93)90050-V","article-title":"Molecular biology of somatostatin receptors","volume":"16","author":"Bell","year":"1993","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2025.178053_bib9","first-page":"289","article-title":"Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article","volume":"72","author":"Bhattacharya","year":"2009","journal-title":"Acta Gastroenterol. Belg."},{"key":"10.1016\/j.ejphar.2025.178053_bib10","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(05)65744-3","article-title":"Octreotide-induced pancreatitis: an effect of increased contractility of oddi sphincter","volume":"348","author":"Bodemar","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178053_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/B978-0-12-800174-5.00007-7","article-title":"The somatostatin receptor in human pancreatic \u03b2-cells","volume":"95","author":"Braun","year":"2014","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.ejphar.2025.178053_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s12325-009-0035-4","article-title":"Lanreotide for the treatment of acromegaly","volume":"26","author":"Castinetti","year":"2009","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejphar.2025.178053_bib13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","article-title":"Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus pegvisomant","volume":"73","author":"Chiloiro","year":"2021","journal-title":"Endocrine"},{"key":"10.1016\/j.ejphar.2025.178053_bib14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178053_bib15","first-page":"CD002233","article-title":"Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients","volume":"2010","author":"D'Amico","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2025.178053_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0026-0495(90)90208-T","article-title":"Somatostatin secretion and action in the regulation of growth hormone secretion","volume":"39","author":"Frohman","year":"1990","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2025.178053_bib17","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/liv.12726","article-title":"Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial","volume":"35","author":"Gevers","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.ejphar.2025.178053_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1590\/1806-9282.20211224","article-title":"Comparison between somatostatin analog injections","volume":"68","author":"Gezer","year":"1992","journal-title":"Rev. Assoc. Med. Bras."},{"key":"10.1016\/j.ejphar.2025.178053_bib19","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1517\/14740338.2015.1059817","article-title":"Adverse events associated with somatostatin analogs in acromegaly","volume":"14","author":"Grasso","year":"2015","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2025.178053_bib20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/gut.35.3_Suppl.S1","article-title":"Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects","volume":"35","author":"Harris","year":"1994","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2025.178053_bib21","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.178053_bib22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gut.38.5.775","article-title":"Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones","volume":"38","author":"Hussaini","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2025.178053_bib23","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/MPA.0b013e3181db01a8","article-title":"A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy","volume":"39","author":"Joseph","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.ejphar.2025.178053_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1399-5448.2009.00547.x","article-title":"Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism","volume":"11","author":"Laje","year":"2010","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.ejphar.2025.178053_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40264-016-0486-x","article-title":"Hepatic cyst infection during use of the somatostatin analog lanreotide in autosomal dominant polycystic kidney disease: an interim analysis of the randomized open-label multicenter DIPAK-1 study","volume":"40","author":"Lantinga","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2025.178053_bib26","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0140-6736(06)69525-1","article-title":"Necrotising enterocolitis","volume":"368","author":"Lin","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178053_bib27","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178053_bib28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/mge.2002.122614","article-title":"Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial","volume":"55","author":"Manolakopoulos","year":"2002","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.ejphar.2025.178053_bib29","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.178053_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/pds.4144","article-title":"Octreotide use and safety in infants with hyperinsulinism","volume":"26","author":"McMahon","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejphar.2025.178053_bib31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2020.20317","article-title":"Acute pancreatitis: a review","volume":"325","author":"Mederos","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2025.178053_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/RLU.0000000000004203","article-title":"Dose-limiting bone marrow toxicities after peptide receptor radionuclide therapy are more prevalent in women than in men","volume":"47","author":"Minczeles","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.ejphar.2025.178053_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2036.2001.00924.x","article-title":"Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during sandostatin LAR","volume":"15","author":"Moschetta","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178053_bib34","first-page":"1652","article-title":"[A case of octreotide acetate-induced acute pancreatitis]","volume":"104","author":"Nagata","year":"2007","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.ejphar.2025.178053_bib35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2169\/internalmedicine.33.593","article-title":"Octreotide decreases biliary and pancreatic exocrine function, and induces steatorrhea in healthy subjects","volume":"33","author":"Nakamura","year":"1994","journal-title":"Intern. Med."},{"key":"10.1016\/j.ejphar.2025.178053_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.ejphar.2025.178053_bib37","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/gut.30.9.1165","article-title":"Therapeutic potential of a long acting somatostatin analogue in gastrointestinal diseases","volume":"30","author":"O'Donnell","year":"1989","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2025.178053_bib38","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2265.2007.02811.x","article-title":"Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems","volume":"66","author":"Paisley","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejphar.2025.178053_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2015.05.007","article-title":"Therapeutic uses of somatostatin and its analogues: current view and potential applications","volume":"152","author":"Rai","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178053_bib40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11154-023-09858-6","article-title":"Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors","volume":"25","author":"Ruggeri","year":"2024","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.ejphar.2025.178053_bib41","first-page":"24","article-title":"[Medication-related diarrhea]","volume":"145","author":"Scheurlen","year":"2003","journal-title":"MMW - Fortschritte Med."},{"key":"10.1016\/j.ejphar.2025.178053_bib42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","article-title":"Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study","volume":"18","author":"Sheppard","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.ejphar.2025.178053_bib43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1210\/endo.141.1.7263","article-title":"Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice","volume":"141","author":"Strowski","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2025.178053_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20123049","article-title":"Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future","volume":"20","author":"Stueven","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.178053_bib45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2174\/1389450116666141205163548","article-title":"Somatostatin and its analogs","volume":"17","author":"Sun","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejphar.2025.178053_bib46","first-page":"161","article-title":"Somatostatin and somatostatin receptors in the immune system: a review","volume":"11","author":"ten Bokum","year":"2000","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.ejphar.2025.178053_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/0003088-200948010-00004","article-title":"Population pharmacokinetic analysis of lanreotide autogel in healthy subjects : evidence for injection interval of up to 2 months","volume":"48","author":"Troc\u00f3niz","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2025.178053_bib48","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1002\/phar.1942","article-title":"Octreotide-associated neutropenia","volume":"37","author":"Tse","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejphar.2025.178053_bib49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/138955713804484794","article-title":"Somatostatin and cognitive function in neurodegenerative disorders","volume":"13","author":"Tuboly","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2025.178053_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000051477","article-title":"The role of octreotide and somatostatin in acute and chronic pancreatitis","volume":"60","author":"Uhl","year":"1999","journal-title":"Digestion"},{"key":"10.1016\/j.ejphar.2025.178053_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/gut.45.1.97","article-title":"A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis","volume":"45","author":"Uhl","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2025.178053_bib52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2362.1994.tb00972.x","article-title":"Somatostatin and the immune and haematopoetic system; a review","volume":"24","author":"van Hagen","year":"1994","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2025.178053_bib53","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bpg.2006.03.008","article-title":"Gallstone disease: primary and secondary prevention","volume":"20","author":"Venneman","year":"2006","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.ejphar.2025.178053_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1440-1746.2004.03186.x","article-title":"Effect of octreotide and corticosteroids on human sphincter of oddi motility","volume":"19","author":"Viazis","year":"2004","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2025.178053_bib55","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.20632","article-title":"Bacterial translocation (BT) in cirrhosis","volume":"41","author":"Wiest","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2025.178053_bib56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejim.2004.06.004","article-title":"ICU management of severe acute pancreatitis","volume":"15","author":"Wilmer","year":"2004","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejphar.2025.178053_bib57","first-page":"1504","article-title":"Octreotide for primary moderate to severe acute pancreatitis: a meta-analysis","volume":"60","author":"Xu","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.ejphar.2025.178053_bib58","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.3748\/wjg.v29.i18.2747","article-title":"Current trends in acute pancreatitis: diagnostic and therapeutic challenges","volume":"29","author":"Zerem","year":"2023","journal-title":"World J. Gastroenterol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:36:24Z","timestamp":1772804184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925008076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":58,"alternative-id":["S0014299925008076"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178053","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world drug safety study of somatostatin analogs based on the food and drug administration adverse event reporting system database","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178053"}}